Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 83.92 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Quick Ratio than Arca Biopharma Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 43, from total ranking in the second quarter 2026 at 124.

Explain Quick Ratio?
How much Cash & cash equivalents ABIO�s has?
What are ABIO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ABIO/financial-strength

https://api.csimarket.com/api/v1/companies/ABIO/fundamentals

https://api.csimarket.com/api/v1/companies/ABIO/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ABIO Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-31.43 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	245.57 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	83.92	Subscribe	Subscribe	Subscribe	Subscribe
ABIO's Total Ranking	# 43	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-43.77 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-45.79 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 3
Healthcare Sector	# 5
Overall Market	# 43

Quick Ratio Statistics
High	Average	Low
87.05	19.65	4.27
(Jun 30 2026)		(Mar 31 2013)

Financial Statements
Arca Biopharma Inc's Current Liabilities	$ 14 Millions	Visit ABIO's Balance sheet
Arca Biopharma Inc's Cash & cash equivalent	$ 1,207 Millions	Visit ABIO's Balance sheet
Source of ABIO's Sales		Visit ABIO's Sales by Geography

Cumulative Arca Biopharma Inc's Quick Ratio

ABIO's Quick Ratio for the trailling 12 Months

ABIO Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	31.02 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	129.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	57.79	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2211	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-8.39 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	25.98 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ABIO Financial Strength Comparisons >> Go to Compare ABIO Quick Ratio to its Competitors

On the trailing twelve months basis ABIO Cash & cash equivalent more than doubled by 245.57 % in Q3 2026 year on year, while Current Liabilities plummeted to $14 millions, this led to increase in in Arca Biopharma Inc's Quick Ratio to 57.79, above ABIO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 378 other companies have achieved higher Quick Ratio than Arca Biopharma Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2208 to 2211.

Explain Quick Ratio?
How much Cash & cash equivalents ABIO�s has?
What are ABIO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 379
Healthcare Sector	# 718
Within the Market	# 2211

trailing twelve months Quick Ratio Statistics
High	Average	Low
43.46	18.33	6.3
(Jun 30 2026)		(Mar 31 2018)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Tyra Biosciences Inc	212.22	$ 700.548 Millions	$ 3.301 Millions
Indaptus Therapeutics Inc	184.44	$ 34.604 Millions	$ 0.188 Millions
Vogenx, Inc.	97.47	$ 82.118 Millions	$ 0.842 Millions
Processa Pharmaceuticals Inc	96.73	$ 180.205 Millions	$ 1.863 Millions
Veradermics Inc	89.45	$ 927.861 Millions	$ 10.373 Millions
Arca Biopharma Inc	83.92	$ 1,206.587 Millions	$ 14.377 Millions
Incannex Healthcare Inc	65.89	$ 68.267 Millions	$ 1.036 Millions
Q32 Bio Inc	56.05	$ 289.587 Millions	$ 5.167 Millions
Rallybio Corporation	51.94	$ 90.693 Millions	$ 1.746 Millions
Enliven Therapeutics Inc	45.41	$ 884.351 Millions	$ 19.473 Millions
Vyne Therapeutics Inc	41.29	$ 268.860 Millions	$ 6.511 Millions
Bicara Therapeutics Inc	40.75	$ 442.346 Millions	$ 10.856 Millions
Xbiotech Inc	39.02	$ 105.037 Millions	$ 2.692 Millions
Tango Therapeutics Inc	38.85	$ 977.503 Millions	$ 25.164 Millions
Trevi Therapeutics Inc	38.05	$ 299.408 Millions	$ 7.869 Millions
Fulcrum Therapeutics Inc	35.70	$ 306.545 Millions	$ 8.587 Millions
Boundless Bio Inc	33.60	$ 62.894 Millions	$ 1.872 Millions
Avalyn Pharma Inc	32.64	$ 422.814 Millions	$ 12.955 Millions
Immix Biopharma Inc	30.89	$ 336.303 Millions	$ 10.889 Millions
Minerva Neurosciences Inc	30.46	$ 76.945 Millions	$ 2.526 Millions
Contineum Therapeutics Inc	30.45	$ 244.484 Millions	$ 8.028 Millions
Pasithea Therapeutics Corp	29.91	$ 82.419 Millions	$ 2.756 Millions
Latigo Biotherapeutics, Inc.	28.73	$ 401.241 Millions	$ 13.964 Millions
Amylyx Pharmaceuticals Inc	26.44	$ 768.132 Millions	$ 29.048 Millions
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Silo Pharma Inc	22.91	$ 8.051 Millions	$ 0.351 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Silence Therapeutics Plc	22.00	$ 247.659 Millions	$ 11.259 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions

Date modified: 2026-11-10T11:44:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.